Antifungal Drugs

Antifungal Drugs Market Outlook

The global antifungal drugs market is projected to reach approximately USD 22 billion by 2035, growing at a CAGR of around 5.5% during the forecast period from 2025 to 2035. This growth can be attributed to several key factors such as the increasing prevalence of fungal infections, a rising geriatric population susceptible to such infections, and the growing awareness regarding the importance of antifungal therapies. Additionally, advancements in drug formulation and the introduction of novel antifungal agents are expected to propel market growth. Other contributing factors include the increase in immunocompromised patients and the rising trend of self-medication, which is driving demand in both hospital and retail settings. The COVID-19 pandemic has further highlighted the need to address fungal co-infections, thereby augmenting the growth trajectory of the antifungal drugs market.

Growth Factor of the Market

The antifungal drugs market is primarily driven by the surge in fungal infections, particularly in immunocompromised patients due to conditions such as HIV/AIDS, cancer, and diabetes. The increasing incidence of these infections leads to a higher demand for effective antifungal therapies, which significantly contributes to market growth. Furthermore, the expanding geriatric population, which is more vulnerable to infections, constitutes another pivotal factor fueling demand for antifungal drugs. The introduction of innovative antifungal agents with enhanced efficacy and reduced side effects is also influencing market dynamics positively. Additionally, the rising awareness regarding fungal infections among healthcare professionals and patients is leading to better diagnosis and treatment options, thus driving market expansion. Finally, the growing trend of self-medication, particularly with over-the-counter antifungal options in retail pharmacies, is further enhancing market potential.

Key Highlights of the Market

• The antifungal drugs market is projected to grow at a CAGR of 5.5% from 2025 to 2035.
• Rising incidence of fungal infections among immunocompromised individuals is a significant growth driver.
• Innovative drug developments and formulations are being introduced to meet the growing demand.
• The geriatric population's vulnerability to infections has intensified the need for antifungal treatments.
• Increased awareness and better diagnostics are leading to improved treatment outcomes.

By Product Type

Azoles:

Azoles are one of the most widely used classes of antifungal medications, primarily indicated for a range of fungal infections. They work by inhibiting the synthesis of ergosterol, a crucial component of fungal cell membranes. This mechanism effectively disrupts the cell membrane, leading to cell death. The azole class encompasses drugs like fluconazole, itraconazole, and voriconazole, which are utilized in treating conditions such as candidiasis, cryptococcal meningitis, and aspergillosis. The growing demand for azole antifungals can be attributed to their broad-spectrum efficacy and relatively favorable safety profile. Furthermore, advancements in formulation technologies have enabled improvements in bioavailability, allowing for oral or intravenous administration, thus enhancing patient compliance and treatment efficacy.

Echinocandins:

Echinocandins represent a newer class of antifungal agents that have gained traction in treating invasive fungal infections, particularly those caused by Candida and Aspergillus species. They target the synthesis of β-(1,3)-D-glucan, an essential component of the fungal cell wall, thereby compromising the structural integrity of the fungus. The primary echinocandins include caspofungin, micafungin, and anidulafungin, which are often reserved for patients with severe or resistant fungal infections. The growing incidence of candidemia and resistant fungal strains has prompted an increase in the utilization of echinocandins within clinical settings, making them a critical component of antifungal therapy. Their favorable pharmacokinetic properties and low toxicity profile further enhance their appeal among healthcare providers.

Polyenes:

Polyenes, such as amphotericin B, are one of the oldest classes of antifungal agents and are primarily used to treat severe systemic fungal infections. They operate by binding to ergosterol in the fungal cell membrane, leading to the formation of pores that cause cell leakage and death. Despite their efficacy, polyenes are often associated with significant side effects, such as nephrotoxicity, which has led to the development of lipid formulations to mitigate these risks. The demand for polyenes remains strong, particularly in hospital settings, due to their broad spectrum of activity against various fungal pathogens. The availability of both conventional and lipid-based formulations has allowed for greater flexibility in treatment options, catering to patients with varying degrees of severity in fungal infections.

Allylamines:

Allylamines, which include terbinafine and naftifine, are primarily used for topical treatment of dermatophyte infections, such as tinea pedis and tinea corporis. They function by inhibiting the enzyme squalene epoxidase, which is vital for ergosterol synthesis in fungal membranes. Due to their localized action and minimal systemic absorption, allylamines are preferred for treating superficial fungal infections and skin conditions. The increasing prevalence of dermatophytosis, coupled with the rising trend of self-medication for skin-related issues, is driving the growth of this segment. The formulation of these drugs into creams, gels, and sprays enhances their usability and patient adherence, which further boosts market demand.

Others:

The category of 'Others' encompasses various antifungal agents that do not fit into the primary classes mentioned above, including newer compounds and combination therapies. This segment has seen substantial growth due to the ongoing research and development efforts aimed at addressing unmet medical needs in antifungal therapy. Emerging antifungal agents, such as isavuconazole and rezafungin, showcase innovative mechanisms of action that may offer advantages over traditional treatments, particularly in managing resistant strains of fungi. Combination therapies are also gaining attention as they can enhance the efficacy while reducing the risk of resistance development. Overall, the 'Others' segment reflects the dynamic nature of antifungal drug development, driven by the necessity to combat emerging fungal infections effectively.

By Application

Aspergillosis:

Aspergillosis is a significant invasive fungal infection caused by the Aspergillus species, particularly affecting immunocompromised individuals. The antifungal drugs approved for treating this condition include azoles (such as voriconazole) and echinocandins. The rising incidence of aspergillosis, especially in patients undergoing chemotherapy or organ transplants, has led to greater demand for effective antifungal therapies targeting this condition. Treatment is often complicated by resistance, making the development of novel agents critical. The increasing awareness of aspergillosis and its associated risks has also fostered a more proactive approach in both diagnosis and treatment, contributing positively to market growth.

Candidiasis:

Candidiasis, primarily caused by Candida albicans and other Candida species, is another major application area for antifungal drugs. It can manifest in various forms, from superficial infections like oral thrush to life-threatening systemic infections. The increasing prevalence of candidiasis, particularly in hospitalized patients and those with weakened immune systems, is driving the demand for antifungal treatments. Echinocandins are often preferred for severe cases due to their efficacy and safety profile. The growing understanding of Candida resistance patterns is influencing treatment guidelines, leading to an increased focus on developing new antifungal agents and combination therapies to effectively manage this prevalent infection.

Dermatophytosis:

Dermatophytosis, or fungal skin infections caused by dermatophytes, is a common condition affecting a significant portion of the population. The primary treatment options include topical agents such as allylamines and azoles, which are effective in managing localized infections. The rising incidences of dermatophytosis, particularly due to increased exposure to risk factors such as sports, communal living, and immunosuppression, are sparking heightened demand for effective antifungal treatments. Additionally, growing consumer awareness regarding skin health and the importance of early treatment options are further driving growth within this segment. The convenience and effectiveness of topical formulations are key factors contributing to the rise in dermatophytosis treatment.

Others:

The 'Others' segment in applications encompasses various less common fungal infections and treatment scenarios, including rare molds and other opportunistic fungi. This category is critical for understanding the overall antifungal market as it accounts for a segment of infections that can occur in specific populations, such as patients with cystic fibrosis or certain malignancies. The complexity of these infections often requires tailored treatment approaches, which may involve a combination of antifungal agents. Research into these less prevalent but clinically significant fungal infections is ongoing, which could lead to the development of specialized treatments and contribute to the expansion of the antifungal drugs market in the coming years.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies play a crucial role in the distribution of antifungal drugs, particularly for patients with severe infections requiring specialized care. These pharmacies are often responsible for managing the procurement, formulation, and dispensing of antifungal medications, ensuring that patients receive appropriate treatment promptly. Given the complexity of antifungal therapy, which may require close monitoring and dose adjustments, hospital pharmacies are typically staffed by clinical pharmacists who can provide valuable input on therapeutic decisions. The increasing volume of patients with serious fungal infections, driven by factors such as rising hospitalization rates and more aggressive cancer therapies, is significantly boosting the demand for antifungal products in hospital settings.

Retail Pharmacies:

Retail pharmacies serve as a vital distribution channel for antifungal drugs, particularly for over-the-counter medications used for treating mild and localized infections. The convenience of accessing antifungal treatments in retail settings makes it easier for consumers to seek relief from common conditions such as athlete's foot or nail fungus. As patients increasingly turn to self-care options for managing minor fungal infections, the demand for topical antifungal agents in retail pharmacies has surged. Moreover, ongoing marketing initiatives and awareness campaigns conducted by manufacturers are influencing consumer behavior and driving sales in this channel, ultimately contributing to the overall growth of the antifungal drugs market.

Online Pharmacies:

Online pharmacies have emerged as a significant distribution channel for antifungal drugs, providing consumers with the convenience of purchasing medications from the comfort of their homes. This trend has accelerated due to the growing acceptance of e-commerce in the healthcare sector, particularly during the COVID-19 pandemic. Online platforms often offer a broader range of products, including both prescription and over-the-counter antifungal agents, catering to a diverse customer base. The ability to compare prices, access customer reviews, and receive discreet delivery has made online pharmacies an appealing option for many patients. This shift towards digital purchasing is anticipated to enhance the overall accessibility and reach of antifungal medications, promoting market growth.

By Ingredient Type

Fluconazole:

Fluconazole is a widely utilized antifungal medication, particularly effective against Candida infections and cryptococcal meningitis. Its broad-spectrum activity and favorable pharmacokinetic profile make it a preferred choice for both empirical and targeted therapy. Fluconazole is often administered orally or intravenously and is recognized for its safety and efficacy, leading to its extensive use in both hospital and outpatient settings. The increasing prevalence of candidiasis, especially among immunocompromised patients, has propelled the demand for fluconazole, establishing it as a cornerstone in antifungal treatment regimens. Furthermore, the availability of generic formulations has made fluconazole more accessible, contributing further to its prominent market presence.

Caspofungin:

Caspofungin, an echinocandin, is primarily used for treating invasive fungal infections caused by Candida and Aspergillus species. Its mechanism of action involves inhibiting β-(1,3)-D-glucan synthesis, making it particularly effective against resistant strains of fungi. The growing incidence of candidemia and the need for effective treatment options for immunocompromised patients have led to increased utilization of caspofungin in clinical practice. The drug's favorable safety profile, combined with its efficacy in severe infections, positions it as a critical option in antifungal therapy. Ongoing research into its use in combination therapies may further enhance its therapeutic capabilities and market demand.

Amphotericin B:

Amphotericin B is a polyene antifungal agent known for its potent activity against a broad spectrum of fungi, particularly in severe systemic infections. Despite its long history of use, amphotericin B is associated with notable side effects, including nephrotoxicity, which has led to the development of lipid formulations aimed at reducing these risks. Amphotericin B remains a vital treatment option in serious fungal infections, particularly in immunocompromised patients. The continued prevalence of such infections ensures that amphotericin B retains a significant share of the antifungal drugs market. Research into optimizing its use and minimizing adverse effects continues to be a vital area of investigation as the medical community seeks to enhance treatment outcomes.

Terbinafine:

Terbinafine, an allylamine antifungal, is primarily used in the treatment of dermatophyte infections, including tinea pedis and tinea corporis. It works by inhibiting squalene epoxidase, leading to a decrease in ergosterol synthesis and ultimately causing fungal cell death. The drug is available in both topical and oral formulations, providing flexibility in treatment options based on infection severity. The increasing prevalence of dermatophyte infections has resulted in growing demand for terbinafine, particularly in outpatient settings where patients seek accessible and effective treatment for skin-related conditions. Ongoing marketing efforts and consumer awareness initiatives are further driving its uptake in the marketplace.

Others:

The 'Others' category in ingredient types includes various antifungal agents that do not fit into the primary classes mentioned above. This can encompass emerging agents with novel mechanisms of action or those in clinical development targeting resistant fungal infections. The introduction of these new agents is crucial for addressing the evolving challenge of antifungal resistance, which poses significant risks to patient outcomes. Additionally, combination therapies that leverage multiple antifungal agents are gaining traction, providing healthcare professionals with more robust treatment options. The ongoing research and development efforts within this segment highlight the dynamic nature of antifungal drug development and the continuous need for innovation in addressing fungal infections.

By Region

The North American antifungal drugs market is expected to hold the largest share, projected to exceed USD 9 billion by 2035, largely driven by the high prevalence of fungal infections and robust healthcare infrastructure. The region benefits from advanced research facilities and a strong focus on pharmaceutical innovation, leading to the rapid introduction of new antifungal therapies. Increased awareness of fungal infections among healthcare providers and patients is also a significant factor contributing to market growth. Additionally, supportive regulatory frameworks and improved access to antifungal treatments further bolster the market landscape in North America, ensuring sustained growth during the forecast period.

Europe is anticipated to follow closely behind North America, with a market size projected to reach approximately USD 7 billion by 2035. The European market is characterized by a growing geriatric population, which is particularly susceptible to fungal infections, thus driving demand for effective antifungal therapies. Furthermore, the increasing incidence of conditions such as diabetes and cancer has contributed to the rising prevalence of fungal infections in this region. Novel antifungal agents and combination therapies are being developed to address the growing concerns of antifungal resistance, ensuring that the European market remains competitive. The CAGR for the European antifungal drugs market is expected to reach around 5% during the forecast period.

Opportunities

Opportunities in the antifungal drugs market are substantial, fueled by the ongoing research and development efforts aimed at tackling the growing incidence of fungal infections. The emergence of new pathogens and the challenge of antifungal resistance necessitate the development of innovative therapies that can provide effective treatment options. Investment in research for novel antifungal agents, particularly those that target resistant strains, is expected to yield significant advancements in the field. Furthermore, the rising awareness of fungal infections and their associated risks is likely to drive demand for antifungal products across various healthcare settings. The potential for combination therapies that improve treatment outcomes presents an additional opportunity, allowing for synergistic effects and reduced risks of resistance development.

Moreover, the increasing trend of self-medication and the accessibility of online pharmacies are expected to open new avenues for market growth. As patients become more proactive in managing their health, the demand for over-the-counter antifungal treatments is anticipated to increase. Additionally, the expansion of telemedicine and digital healthcare platforms may facilitate broader access to antifungal therapies, particularly for rural and underserved populations. By harnessing these emerging trends and addressing gaps in treatment, stakeholders in the antifungal drugs market can position themselves to capitalize on growth opportunities over the coming years.

Threats

Despite the promising growth outlook, the antifungal drugs market faces several threats that could impede its progress. One of the foremost challenges is the rising incidence of antifungal resistance, which is undermining the efficacy of existing treatments. The emergence of resistant fungal strains poses a significant threat to public health and complicates treatment protocols, necessitating the urgent development of new antifungal therapies. Additionally, the high costs associated with research and development, particularly for novel antifungal agents, present a barrier to entry for many companies in the market. The stringent regulatory requirements for drug approval further exacerbate these challenges, leading to increased timelines and costs for bringing new products to market.

Moreover, the market is also influenced by the potential for adverse side effects associated with antifungal medications, which may limit their use in certain patient populations. Instances of nephrotoxicity or hepatotoxicity in some antifungal treatments can deter healthcare providers from prescribing these agents, particularly in vulnerable populations. Furthermore, the ongoing COVID-19 pandemic has shifted healthcare priorities and resources, potentially diverting attention away from fungal infections. As healthcare systems focus on managing the pandemic, the attention and funding directed towards antifungal drug development may be affected, posing additional risks to the market.

Competitor Outlook

• Pfizer Inc.
• Merck & Co., Inc.
• Astellas Pharma Inc.
• Bristol-Myers Squibb Company
• Gilead Sciences, Inc.
• Novartis AG
• Roche Holding AG
• Sanofi S.A.
• GlaxoSmithKline plc
• Helsinn Healthcare SA
• Teva Pharmaceutical Industries Ltd.
• Amgen Inc.
• AbbVie Inc.
• Fresenius Kabi AG
• Mylan N.V.

The competitive landscape of the antifungal drugs market is characterized by a mix of established pharmaceutical giants and emerging biotech firms focused on addressing the pressing need for effective antifungal therapies. Key players such as Pfizer and Merck have long dominated the market with their extensive portfolios of antifungal agents, leveraging their research and development strengths to innovate and deliver new therapies. These companies invest significantly in clinical trials and regulatory processes to ensure that their products meet the evolving needs of healthcare professionals and patients alike. The emphasis on expanding therapeutic indications for existing drugs, coupled with the development of novel agents, underscores the competitive nature of this landscape.

Additionally, smaller biotech companies are increasingly entering the antifungal space, driven by the urgent need to address antifungal resistance and the rising prevalence of fungal infections. These firms often focus on niche markets, developing targeted therapies for specific fungal infections or resistant strains. Collaborations and partnerships between larger pharmaceutical companies and biotech firms are common, aiming to combine resources and expertise to accelerate the development of innovative antifungal treatments. The dynamic nature of this competitive landscape is indicative of the ongoing challenges and opportunities present within the antifungal drugs market.

Among the major players, Gilead Sciences has gained recognition for its contributions to the development of novel antifungal agents, particularly in the context of invasive fungal infections. The company’s commitment to research in this area has resulted in significant advancements in treatment options for patients with complicated infections. Similarly, Astellas Pharma has positioned itself as a leader in the echinocandin category, emphasizing its focus on addressing the needs of patients with challenging fungal infections. The ongoing commitment to improving treatment outcomes through innovation and collaboration will continue to shape the competitive landscape, as companies strive to meet the demands of an evolving healthcare environment.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Mylan N.V.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 AbbVie Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Novartis AG
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Pfizer Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Sanofi S.A.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Roche Holding AG
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Fresenius Kabi AG
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Merck & Co., Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 GlaxoSmithKline plc
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Astellas Pharma Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Gilead Sciences, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Helsinn Healthcare SA
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Bristol-Myers Squibb Company
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Antifungal Drugs Market, By Application
    • 6.1.1 Aspergillosis
    • 6.1.2 Candidiasis
    • 6.1.3 Dermatophytosis
    • 6.1.4 Others
  • 6.2 Antifungal Drugs Market, By Product Type
    • 6.2.1 Azoles
    • 6.2.2 Echinocandins
    • 6.2.3 Polyenes
    • 6.2.4 Allylamines
    • 6.2.5 Others
  • 6.3 Antifungal Drugs Market, By Ingredient Type
    • 6.3.1 Fluconazole
    • 6.3.2 Caspofungin
    • 6.3.3 Amphotericin B
    • 6.3.4 Terbinafine
    • 6.3.5 Others
  • 6.4 Antifungal Drugs Market, By Distribution Channel
    • 6.4.1 Hospital Pharmacies
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Antifungal Drugs Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Antifungal Drugs market is categorized based on

By Product Type

• Azoles
• Echinocandins
• Polyenes
• Allylamines
• Others

By Application

• Aspergillosis
• Candidiasis
• Dermatophytosis
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Ingredient Type

• Fluconazole
• Caspofungin
• Amphotericin B
• Terbinafine
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Pfizer Inc.
• Merck & Co., Inc.
• Astellas Pharma Inc.
• Bristol-Myers Squibb Company
• Gilead Sciences, Inc.
• Novartis AG
• Roche Holding AG
• Sanofi S.A.
• GlaxoSmithKline plc
• Helsinn Healthcare SA
• Teva Pharmaceutical Industries Ltd.
• Amgen Inc.
• AbbVie Inc.
• Fresenius Kabi AG
• Mylan N.V.